RT Journal Article SR Electronic T1 SILYBIN INACTIVATES CYTOCHROMES P450 3A4 AND 2C9 AND INHIBITS MAJOR HEPATIC GLUCURONOSYLTRANSFERASES JF Drug Metabolism and Disposition JO Drug Metab Dispos FD American Society for Pharmacology and Experimental Therapeutics SP 587 OP 594 DO 10.1124/dmd.32.6.587 VO 32 IS 6 A1 Chitra Sridar A1 Theunis C. Goosen A1 Ute M. Kent A1 J. Andrew Williams A1 Paul F. Hollenberg YR 2004 UL http://dmd.aspetjournals.org/content/32/6/587.abstract AB Silybin, a major constituent of the milk thistle, is used to treat several liver disorders. Silybin inactivated purified, recombinant cytochromes P450 (P450) 3A4 and 2C9 in a mechanism-based manner. The inactivations were time-, concentration-, and NADPH-dependent. The inactivation of the 7-benzyloxy-4-(trifluoromethyl-)coumarin O-debenzylation activity (P450 3A4) was characterized by a KI of 32 μM, a kinact of 0.06 min-1, and a t1/2 of 14 min. Testosterone metabolism to 6-β-hydroxytestosterone (P450 3A4) was also inactivated with a KI of 166 μM, a kinact of 0.08 min-1, and a t1/2 of 9 min. The 7-ethoxy-4-(trifluoromethyl)coumarin O-deethylation activity of purified human P450 2C9 was inactivated with a KI of 5 μM, a kinact of 0.14 min-1, and a t1/2 of 7 min. Parallel loss of heme was observed with both P450s. Activity of both P450 enzymes was not recovered after removal of silybin either by dialysis or by spin gel filtration. In addition, silybin inhibited the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin catalyzed by recombinant hepatic UDP-glucuronosyltransferases (UGTs) 1A1, 1A6, 1A9, 2B7, and 2B15, with IC50 values of 1.4 μM, 28 μM, 20 μM, 92 μM, and 75 μM, respectively. Silybin was a potent inhibitor of UGT1A1 and was 14- and 20-fold more selective for UGT1A1 than for UGT1A9 and UGT1A6, respectively. Thus, careful administration of silybin with drugs primarily cleared by P450s 3A4 or 2C9 is advised, since drug-drug interactions cannot be excluded. The clinical significance of in vitro UGT1A1 inhibition is unknown. The American Society for Pharmacology and Experimental Therapeutics